Baidu
map

2015年默克雪兰诺中国生殖医学研究基金CREATE 标书征集圆满完成

2015-04-10 MedSci MedSci原创

2015年默克雪兰诺中国生殖医学研究基金(MerckSerono China Research Fund for Fertility Experts, CREATE基金)自2014年11月份开始征集以来,获得广大生殖领域临床医生的积极参与和热烈反馈,截止2015年3月31日标书截止日,共收到标书180余份。 基金研究方向涉及反复种植失败、多囊卵巢综合、胚胎发育潜能、卵巢低反应等生殖领域热点话

2015年默克雪兰诺中国生殖医学研究基金(MerckSerono China Research Fund for Fertility Experts, CREATE基金)自2014年11月份开始征集以来,获得广大生殖领域临床医生的积极参与和热烈反馈,截止2015年3月31日标书截止日,共收到标书187份。


基金研究方向涉及反复种植失败、多囊卵巢综合征、胚胎发育潜能、卵巢低反应等生殖领域热点话题。

在随后的评审过程中,CREATE专家评审委员会将秉承精益求精的专业态度,以客观严谨、公开公正的原则对待每一位投标者,最终CREATE资助结果将于2015年6月30日后公布。在收获标书征集成功的同时,也希望广大生殖领域医生能通过CREATE基金提升科研能力 ,启发科研思路,使CREATE基金成为生殖领域中青年医生提升科研素养的专业平台。

背景信息:
CREATE基金由默克雪兰诺有限公司于2014年3月正式设立,旨在鼓励中国优秀中、青年学者开展针对生殖医学的临床研究(Clinical Research)及转化型医学研究(Translational Research),促进对不孕症治疗的深入研究,增进生殖医学专业工作者之间的研究合作与学术交流。宗旨是改善辅助生殖治疗的结局,并最终提高活产率 。

2014年CREATE基金共收到108份CREATE基金申请方案,经过严格的评审,最终有17份研究方案获得CREATE基金资助。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
    2015-04-12 chenshujs
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1775977, encodeId=c6e21e759778b, content=<a href='/topic/show?id=ff0b690e069' target=_blank style='color:#2F92EE;'>#生殖医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69070, encryptionId=ff0b690e069, topicName=生殖医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e98138855513, createdName=fusion, createdTime=Thu Dec 17 03:27:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992008, encodeId=8303199200890, content=<a href='/topic/show?id=eae710335997' target=_blank style='color:#2F92EE;'>#默克雪兰诺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103359, encryptionId=eae710335997, topicName=默克雪兰诺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Jun 07 22:27:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273880, encodeId=c91612e388008, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495727, encodeId=0eea1495e27df, content=<a href='/topic/show?id=3c4161912a4' target=_blank style='color:#2F92EE;'>#标书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61912, encryptionId=3c4161912a4, topicName=标书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ea09191365, createdName=chenshujs, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543593, encodeId=31871543593e7, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581451, encodeId=b45d158145106, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 12 02:27:00 CST 2015, time=2015-04-12, status=1, ipAttribution=)]
    2015-04-12 医者仁心

相关资讯

CREATE研究五年结果:EXCEL支架的长期安全性值得肯定

   “CREATE5年研究取得的进展和结果证明,在我国完全真实世界PCI临床实践中,应用EXCEL支架安全有效,而且也提示了使用这种新型可降解涂层技术的药物洗脱支架,与国际上普遍主张延长DES术后双联抗血小板疗程至1年以上相比,无论何种患者及病变类型,使用EXCEL支架术后氯吡格雷和阿司匹林双联抗血小板治疗仅需持续6个月,短于目前多数DES术后用药时间,而且能够大幅降低晚期血

CREATE研究五年结果公布

背景 自1977年德国医生格林特齐希(Gruentzig)在苏黎世成功完成世界首例经皮腔内冠状动脉成形术(PTCA)起,冠心病的治疗就进入了一个新纪元。从最初的单纯球囊扩张术,冠心病介入治疗经历了30余年的发展,已经进入第三代药物支架时代。与第一代裸金属支架(BMS)、第二代药物洗脱支架(DES)相比,第三代使用生物可降解涂层技术(聚合物涂层在支架置入后3~6个月内可自动降解为CO2和H2O)的

Baidu
map
Baidu
map
Baidu
map